Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MXCT
MXCT logo

MXCT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy MaxCyte Inc (MXCT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.870
1 Day change
2.95%
52 Week Range
2.960
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

MaxCyte Inc (MXCT) is not a strong buy at this moment for a beginner investor with a long-term horizon. While the stock is trading at a significant discount to its cash per share, the company's financial performance has been weak, with declining revenue, net income, and EPS. Additionally, there are no recent positive news catalysts or significant trading trends to support a strong bullish case. The technical indicators are neutral, and no proprietary trading signals (AI Stock Picker or SwingMax) are present today. For now, it is better to hold off on investing in MXCT until more favorable conditions emerge.

Technical Analysis

The MACD is slightly positive at 0.0144, indicating mild bullish momentum, but it is contracting. RSI is neutral at 59.451, and moving averages are converging, showing no clear trend. Key support is at 0.77, and resistance levels are at 0.89 and 0.928. The stock is trading pre-market at 0.8616, slightly above the pivot level of 0.83, indicating limited immediate upside potential.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
10

Positive Catalysts

  • The company is making progress in supporting late-stage programs and launching a new product to build its early-stage customer pipeline. Analysts believe the stock is trading at a 50% discount to its cash per share, presenting an attractive risk-to-reward profile.

Neutral/Negative Catalysts

  • The company reported a weak quarter with declining revenue (-16.02% YoY), net income (-9.45% YoY), and EPS (-10.00% YoY). There are no significant trading trends from hedge funds or insiders, and no recent news or congress trading data to act as a catalyst.

Financial Performance

In 2025/Q4, revenue dropped to $7.3M (-16.02% YoY), net income dropped to -$9.596M (-9.45% YoY), and EPS dropped to -$0.09 (-10.00% YoY). However, gross margin increased to 63.68% (+2.66% YoY), indicating some operational efficiency improvements.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Craig-Hallum recently lowered the price target from $7 to $5 but maintained a Buy rating, citing strong fundamentals and progress despite a weak quarter. The firm highlights the stock's significant discount to cash per share as an attractive factor.

Wall Street analysts forecast MXCT stock price to rise
5 Analyst Rating
Wall Street analysts forecast MXCT stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.847
sliders
Low
4.94
Averages
6.92
High
8.89
Current: 0.847
sliders
Low
4.94
Averages
6.92
High
8.89
Craig-Hallum
Buy
downgrade
$7 -> $5
AI Analysis
2026-03-25
Reason
Craig-Hallum
Price Target
$7 -> $5
AI Analysis
2026-03-25
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on MaxCyte to $5 from $7 and keeps a Buy rating on the shares. The firm notes the company reported an ostensibly weak quarter. However, Craig-Hallum points out that the company continues to make solid progress and that its fundamentals remain strong. In addition to supporting more late-stage programs than ever and launching a new product designed to build the early-stage customer pipeline, the firm believes that with the stock currently trading at a 50% discount to cash per share, the risk-to-reward profile is attractive.
BTIG
BTIG
Buy
to
Neutral
downgrade
2025-08-11
Reason
BTIG
BTIG
Price Target
2025-08-11
downgrade
Buy
to
Neutral
Reason
BTIG downgraded MaxCyte to Neutral from Buy without a price target after \"a tough Q2 business update\" and lowering of the bar for 2025. MaxCyte lowered its 2025 revenue guide by $5M, or 14% of its business, citing ongoing challenges for many of its cell and gene therapy customers to obtain capital to fund programs, purchase capital, or lease its systems, the analyst noted. The firm thinks the company still has a best-in-class electroporation platform, arguing that the \"number one driver to turn the business around is simply its customers becoming more readily able to raise money and invest in more programs.\"
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MXCT
Unlock Now

People Also Watch